Physician profile
Jill D Powell
NPI 1295876449
$3,856.48
in general payments reported to CMS, 2019-2025
26 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $647 · 2021: $725 · 2022: $760 · 2023: $508 · 2024: $324 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $894.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $495.68 | 2021-2025 | |
| Lilly USA, LLC | $349.25 | 2019-2023 | Trulicity, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $318.87 | 2019-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $256.26 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $225.37 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $198.41 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $112.16 | 2021-2024 | |
| Abbott Laboratories | $101.26 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.48 | 2021-2023 | Jardiance |
| Allergan, INC. | $91.41 | 2020 | |
| Eisai INC. | $84.86 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $75.31 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $74.50 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $73.00 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $68.31 | 2022 | |
| Astellas Pharma US INC | $67.05 | 2022-2024 | Veozah |
| Amarin Pharma, INC. | $63.51 | 2019-2020 | |
| Lundbeck LLC | $40.44 | 2022-2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $39.02 | 2021 | |
| Radius Health, INC. | $38.15 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $33.05 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $20.53 | 2020 | |
| Seqirus USA INC | $18.24 | 2025 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $13.53 | 2019 | |
| Horizon Therapeutics Plc | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.